The global incidence rate of non-alcoholic fatty liver disease (NAFLD) is approximately 25%.
With the global increase in obesity and its associated metabolic syndromes, NAFLD has …

Increased incidence of liver diseases emphasizes greater caution in prescribing
antirheumatic drugs due to their hepatotoxicity. A transient elevation of transaminases to …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, placing an increasing burden on human health. NAFLD is a complex …

The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in
the liver in combination with metabolic dysfunction in the form of overweight or obesity and …

An international panel recently proposed an update to the terminology and diagnostic
criteria for fatty liver disease. The experts proposed a change in the nomenclature from non …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition
characterized by hepatic fat accumulation combined with underlying metabolic …

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this
nomenclature MAFLD was proposed to renovate its former name, nonalcoholic fatty liver …

Non-alcoholic fatty liver disease (NAFLD) includes simple steatosis, a benign condition, and
non-alcoholic steatohepatitis, a condition that beyond TG accumulation also includes …

Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver
disease affecting both adults and children in the USA and many other parts of the world …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …